Diabetes Clinical Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA.
Diabetes Clinical Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA
Diabetes Care. 2020 Apr;43(4):913-917. doi: 10.2337/dc19-1731. Epub 2020 Feb 4.
Most individuals with two or more islet autoantibodies progress to clinical type 1 diabetes. However, in some individuals, autoantibodies are subsequently lost. Here, our objectives were to determine the frequency of autoantibody loss (reversion) in multiple-autoantibody-positive individuals and to determine the association between reversion and progression to clinical disease.
We analyzed multiple-autoantibody-positive individuals participating in TrialNet's Pathway to Prevention Study for reversion and determined the effect of reversion on progression to clinical disease using a Cox regression analysis.
Of 3,284 multiple-autoantibody-positive subjects, reversion occurred in 134 (4.1%) and was associated with reduced incidence of clinical disease. Reversion occurred more frequently with older age, lower autoantibody titers, and fewer positive autoantibodies.
Although reversion of multiple-autoantibody positivity is rare, when it occurs, the risk of progressing to clinical disease is reduced. This suggests unknown mechanisms promoting immune remission in some individuals.
大多数同时存在两种或以上胰岛自身抗体的个体将进展为临床 1 型糖尿病。然而,在某些个体中,自身抗体随后会消失。在此,我们的目的是确定多自身抗体阳性个体中自身抗体消失(逆转)的频率,并确定逆转与进展为临床疾病之间的关联。
我们分析了参与 TrialNet 预防研究路径的多自身抗体阳性个体的逆转情况,并使用 Cox 回归分析确定了逆转对临床疾病进展的影响。
在 3284 名多自身抗体阳性的受试者中,有 134 名(4.1%)发生了逆转,与临床疾病发生率降低相关。逆转更常发生于年龄较大、自身抗体滴度较低和阳性自身抗体较少的个体中。
尽管多自身抗体阳性的逆转较为罕见,但当发生逆转时,进展为临床疾病的风险会降低。这表明在某些个体中存在促进免疫缓解的未知机制。